PQRI Case Study (5): Nonsterile Facility Cleaning Requirements - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

PQRI Case Study (5): Nonsterile Facility Cleaning Requirements
The fifth in a series of eight case studies from the Product Quality Research Institute focuses on nonsterile facility cleaning requirements.

Pharmaceutical Technology
pp. 72-74

Risk control

In this case study, risk as reduced by applying a structured and standardized approach to determine minimum facility cleaning requirements. The frequency was predicated on good scientific principles and an understanding of the facility design, process characteristics (e.g., historical dust generating capabilities), and product susceptibility (e.g., inherent microbial inhibition, water content). Risk was further mitigated by routine facility audits to ensure that cleaning choices and frequencies are sufficient for maintaining facilities in a GMP-compliant state.

Risk communication and documentation

The risk analysis was reviewed by a senior level quality standards committee to gain alignment on operating principles, risk analysis, and risk controls. The resulting tools of the analysis (i.e., the prioritization table and decision tree) are now codified in a company quality guidance document. The quality guidance is used to establish local standard operating procedures for execution at the shop-floor level. Training is performed against the operating procedure and training records are periodically audited for compliance.

Risk review

As part of the firm's standard practice for the ongoing maintenance of quality guidances, the subject risk analysis (defined as part of the company guideline on facility cleaning) is reviewed by subject matter experts on a periodic basis to ensure that the assumptions and decisions remain valid and justified.

Ted Frank is with Merck & Co; Stephen Brooks, Kristin Murray,* and Steve Reich are with Pfizer; Ed Sanchez is with Johnson & Johnson; Brian Hasselbalch is with the FDA Center for Drug Evaluation and Research; Kwame Obeng is with Bristol Myers Squibb; and Richard Creekmore is with AstraZeneca.

*To whom all correspondence should be addressed, at


1. T. Frank et al., Pharm. Technol. 35 (7), pp. 72–79.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here